Latest Ai Technology News

Smart Parking Limited grew its ANPR sites by 17% in Q3 FY26 and increased parking breach notices by 19%, leveraging acquisitions and AI technology to expand across Europe and New Zealand.

Element 25 is making steady progress on its Butcherbird Expansion Project in Western Australia, with major equipment ordered, key contracts nearing finalisation, and project financing advancing toward closure ahead of a Q1 2027 commissioning target.

BrainChip detailed significant progress in its neuromorphic AI technology and commercial strategy at its 2026 AGM, highlighting the AKD1500 chip launch and expanding defense and industrial collaborations.

BrainChip Holdings has signed a global IP license agreement with ASICLAND, enabling integration of its Akida neuromorphic AI technology into custom SoC designs with a royalty-based revenue model.

Light & Wonder (ASX:LNW) posted modest revenue growth in 2025, driven by Gaming and iGaming segments, while SciPlay revenue dipped slightly. The company completed its Grover acquisition, settled a $128 million IP dispute with Aristocrat, and transitioned to a sole ASX listing.

CurveBeam AI reported stable device orders but faces regulatory delays for FDA and China clearances, while securing a A$4 million investment from WEGO Orthopaedics and advancing clinical collaborations with robotic surgery systems.

Axtec Limited has sold its PaySure loan book to Real Flow and secured a minority stake in the fintech, marking a strategic shift towards a platform-focused, AI-driven distribution model.

Green & Gold Minerals (ASX: GG1) is gearing up to drill at its Copper Hills project in Queensland after releasing historic and new data showing high-grade copper, silver, and indium mineralisation. The Herberton Conductor Metals Project is shaping as a polymetallic hotspot with potential ties to electrification and AI sectors.

icetana AI has landed a US$176,450 SaaS contract through SoftBank Robotics for Japan Reliance Service Corporation, adding around 10% to its annual recurring revenue and highlighting growing demand for AI security in Japan.

Pathkey.AI has secured a significant commercial contract with Imunexus Therapeutics, deploying its AI-driven TrialKey platform to enhance early-phase clinical trial design and capital raising efforts.

Algorae Pharmaceuticals has launched a second collaboration with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its drug development pipeline.

BrainChip Holdings has inked a global licensing agreement with Korea’s EDGEAI, granting access to its Akida 2 neuromorphic AI technology for EDGEAI’s upcoming semiconductor products. The deal includes milestone payments and royalties, marking a significant step in BrainChip’s global expansion and the growing edge AI market.